Prostate cancer diagnosis and characterization with mass spectrometry imaging.
Prostate cancer diagnosis and characterization with mass spectrometry imaging.
复制标题
DOI：
10.1038/s41391-017-0011-z
复制
发表时间：
2018-09
影响因子：
4.8
通讯作者：
Cheng LL
中科院分区：
文献类型：
--
作者：
Kurreck A;Vandergrift LA;Fuss TL;Habbel P;Agar NYR;Cheng LL
前列腺癌（PCa）是美国男性中最常见的癌症和癌症死亡的第二大原因，提出了区分惰性和侵袭性肿瘤以进行适当治疗的临床挑战。PCa在代谢途径中呈现显著改变，其可以潜在地使用如质谱（MS）或质谱成像（MSI）的技术来测量，并用于表征PCa侵袭性。MS量化生物系统的代谢组学、蛋白质组学和脂质组学特征，这些特征可以通过MSI进一步可视化其空间分布。在PubMed中查询了2007年4月至2017年4月期间与人类前列腺癌MS和MSI相关的所有出版物。为了评价MSI在人PCa诊断和鉴别中的实用性，选择了报告PCa特异性代谢物或指示PCa侵袭性的代谢物的研究的MSI文章进行纳入。纳入了涵盖MS和MSI原理、局限性和PCa应用的文章。我们在完整的人类前列腺组织标本中确定了9项关于MSI的关键研究，这些研究确定了可以区分良性和恶性前列腺组织或指示前列腺癌侵袭性的代谢物。这些MSI检测到的生物标志物在可靠地识别PCa和确定疾病侵袭性方面显示出希望。MSI代表了一种创新技术，能够询问与组织病理学相关的癌症生物标志物并研究肿瘤侵袭性。我们建议MSI作为一个强大的辅助组织病理学成像工具，前列腺组织评价，这种离体技术的临床翻译可能使用MSI的个性化医疗在前列腺癌的诊断和预后。此外，从这项技术提供的知识可以主要有助于PCa和其他恶性疾病的分子发病机制的理解。
Prostate cancer (PCa), the most common cancer and second leading cause of cancer death in American men, presents the clinical challenge of distinguishing between indolent and aggressive tumors for proper treatment. PCa presents significant alterations in metabolic pathways that can potentially be measured using techniques like mass spectrometry (MS) or mass spectrometry imaging (MSI) and used to characterize PCa aggressiveness. MS quantifies metabolomic, proteomic, and lipidomic profiles of biological systems that can be further visualized for their spatial distributions through MSI. PubMed was queried for all publications relating to MS and MSI in human prostate cancer from April 2007 to April 2017. With the goal of reviewing the utility of MSI in diagnosis and prognostication of human PCa, MSI articles that reported investigations of PCa-specific metabolites or metabolites indicating PCa aggressiveness were selected for inclusion. Articles were included that covered MS and MSI principles, limitations, and applications in PCa. We identified nine key studies on MSI in intact human prostate tissue specimens that determined metabolites which could either differentiate between benign and malignant prostate tissue or indicate prostate cancer aggressiveness. These MSI-detected biomarkers show promise in reliably identifying PCa and determining disease aggressiveness. MSI represents an innovative technique with the ability to interrogate cancer biomarkers in relation to tissue pathologies and investigate tumor aggressiveness. We propose MSI as a powerful adjuvant histopathology imaging tool for prostate tissue evaluations, where clinical translation of this ex vivo technique could make possible the use of MSI for personalized medicine in diagnosis and prognosis of prostate cancer. Moreover, the knowledge provided from this technique can majorly contribute to the understanding of molecular pathogenesis of PCa and other malignant diseases.
登录
查看更多内容
DOI：
10.1073/pnas.1408129111
发表时间：
2014-10-21
影响因子：
11.1
作者：
Calligaris, David;Caragacianu, Diana;Agar, Nathalie Y. R.
通讯作者：
Agar, Nathalie Y. R.
影响因子：
4.8
作者：
Gibbs, Peter E. M.;Miralem, Tihomir;Maines, Mahin D.
通讯作者：
Maines, Mahin D.
影响因子：
7.4
作者：
Eberlin, Livia S.;Dill, Allison L.;Costa, Anthony B.;Ifa, Demian R.;Cheng, Liang;Masterson, Timothy;Koch, Michael;Ratliff, Timothy L.;Cooks, R. Graham
通讯作者：
Cooks, R. Graham
影响因子：
2.1
作者：
Chan, TY;Partin, AW;Epstein, JI
通讯作者：
Epstein, JI
影响因子：
11.5
作者：
Cazares, Lisa H.;Troyer, Dean;Semmes, O. John
通讯作者：
Semmes, O. John